Guilherme Perini, MD (@GuiperiniMD) profile picture

Hematologist in Sao Paulo, Brazil. Focus on Lymphomas and CLL Host: Fase 3 Podcast Host: Happy Auer Podcast

Sao Paulo, Brazil
Joined August 2020
Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)Photo by Guilherme Perini, MD (@GuiperiniMD)
You have to be always drunk. That's all there is to it; it's the only way. So as not to feel the horrible burden of time that breaks your back and bends you to the earth, you have to be continually drunk. But on what? Wine, poetry or virtue, as you wish. But be drunk Baudelaire
26
7,237
#PeriniPicks no. 9 for #ASH26 This is actually a 2 abstract Pick for the same problem: long term toxicity of steroids. First, the Sail trial of Adrenal Insufficiency (6.2%) of lymphoma patients treated with steroids. Long term toxicity (~8 months) with a >2.5 fold risk of mortality (although I see some bias here, since these patients needed more therapy). onlineprogram.hematology.org… Second, risk of fractures after 1st line R-CHOP in >20.000 Korean patients. Another long term toxicity of steroids we don't pay too much attention. onlineprogram.hematology.org…
1
1
4
458
Why is this important? Because first, we need a non-inferiority trial of One day x 5 day steroid in R-CHOP Backbone... Second, because with bispecifics moving on first line therapy, there will be an increase in steroid exposure. We should definitely see how this impact in those long term adverse events...
45
#PeriniPicks for #ASH26 Starting Right Now! And No. 10 is a small ph2 of Lorlatinib, a 3rd generation ALK-inhibitor in R/R ALK+ Malignancies (Mainly lymphomas). Estimated 18-month PFS and OS rates were 75% and 88% onlineprogram.hematology.org… In a very challenging situation, ORR of 100%. Suitable for bridge for Allo. It's beyond time we move on with trials of Lorlatinib + Chemo in first line therapy, especially in ALK+ LBCL.
1
1
9
1,483
Anyone else having trouble seeing the #ASH26 abstracts?
3
4
788
My POV: What % of IPS 3-7 achieves PET2 neg with BRECADD? Not keen to give 6 cycles of BRECADD if it is what it takes for 5% PFS difference. In 10y, secondary neoplasms will take its toll...
BrECADD or nivo-AVD? GHSG and SWOG pooled their patient-level data. Stage III/IV, 18-60: 3-yr PFS 94.9% vs 90.6%, febrile neutropenia 29% vs 6%, OS similar. Weighted, not randomized. Gap mostly in IPS 3-7. Accept more toxicity there? #ASH26 #lymsm #HodgkinLymphoma onlineprogram.hematology.org…
1
2
19
1,801
While impressive, median follow up is short and n is small. Chemo-based regimens + BTKi remains SoC... for now.
Chemo-free 1L MCL at #ASH26 (investigational): GATE1 pirto-ven-R, n=50, 34% TP53-altered: CR 96%, 12-mo PFS 96% (mFU 8 mo) TrAVeRse acala-ven-R, n=108: 22-mo PFS 89%, TP53m 82% TP53m pts doing well early. Next question: is MRD-neg stop safe? @YucaiWangMD #lymsm #MCL
1
5
832
ASH Abstracts are out: Let the games begin! #PeriniPicks #LeonardList #ASH26
7
505
LinfoMondays!
🧬 Linfomondays | LOTIS-9 O estudo LOTIS-9 avaliou loncastuximabe tesirina associado a rituximabe em pacientes idosos, frágeis ou com contraindicação a antraciclinas com LDGCB não tratado. 📚 Confira os principais achados na Hematolog.
4
525
I wish these biespecifics would be tested in Angioimmunoblastic T-cell lymphomas...
PD(L)1-VEGF bispecifics are already beating PD1 inhibition alone in trials, so what's next? This trial (BioNTech, DualityBio, BMS) adds a new B7-H3 ADC to a PDL1-VEGF bispecific, with potential synergy: 1) VEGF blockade: normalizes tumor vasculature, improves ADC delivery and T cell infiltration. 2) B7-H3 ADC: kills cancer cells, triggers immunogenic inflammation. 3) PDL1 blockade: releases immune suppression, allows T cells to exploit immune response induced by ADC. Confirmed ORR up to 71% -- in immune-cold platinum-resistant ovarian cancer. The broader, ongoing phase 2 includes colorectal cancer, pancreatic cancer and other tumor types.
1
1
1
8
863
Guilherme Perini, MD retweeted
On the 3rd anniversary of October 7, it’s important to remember the full hideous horror of what Hamas did that day to the Israeli people - and to condemn it, unequivocally. Those who still refuse to condemn it are complicit in supporting terrorism.
3,134
1,375
272
17,795
1,074,911
Yes, but lets not forget that the RR scenario is in constant improvement. Might take years for an OS benefit. I think if the difference in PFS remains in longer follow ups, we have a winner!
Replying to @tobyeyre82
HR 0.49 certainly has my attention. But before we "CHOP" R-CHOP from the frontline, I want to know we’re actually curing more patients. Frontline DLBCL is curative. My bar for adding a bispecific to R-CHOP is higher than improving PFS alone. Show me the curves. Show me the toxicity. Show me the OS. PFS gets my attention. OS changes my practice.
2
1
9
1,382
Ok, looks like Epco-R-CHOP is ready for primetime. HR 0.49 is impressive, and will probably be the new SoC. What we eagerly wait: 1. Toxicity data 2. How Glofi-Pola-R-CHP will perform in the ph3 trial 3. Molecular data Exciting times ahead!
1
3
1
44
5,314
Guilherme Perini, MD retweeted
This should be pushed far and wide. Watched in every college class in the U.S. Thank you @billmaher The moral confusion is gross. "It is not a genocide, it is a counterattack in a war...Gaza equals genocide is a lie, an easily provable lie (as I have argued from first hand observations in Gaza). The fact that so many democrats go along with it is to me the party's worse moment since they undid reconstruction after the civil war...words have meaning...genocide, kill or try to kill an entire people, you can't just change the definition of genocide to mean counterattack in a war where people including civilians die, that's every war..."
374
4,109
211
16,615
1,031,487
If Anthracycline is Key, why should we celebrate a regimen that has lower dosis of Doxo compared to the ABVD backbone? Let the war begins...
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
12
3,207
This might be the most non-sense idea I have ever read. Whats next? Abandon talking to patients?
1
9
2,487
We only transplant what we dont know how to treat. 🤔🤔🤔🤔🤔
Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma onlinelibrary.wiley.com/doi/… #CLL #leusm
2
1
17
2,555
In his opinion, HD Mtx remains SoC in testicular lymphoma. I agree 100%. Let the fight begin!
I had the opportunity to share a session on DLBCL with Dr. Vitolo. A true honor. And I had the opportunity to ask him about CNS prophylaxis in testicular lymphoma!
2
1
12
2,089